Long‐term safety and sustained efficacy for up to 5 years of treatment with recombinant factor IX Fc fusion protein in subjects with haemophilia B: Results from the B‐YOND extension study

• Published in: Haemophilia : the official journal of the World Federation of Hemophilia Vol. 26; no. 6; pp. e262 - e271
• Main Authors: Pasi, K. John, Fischer, Kathelijn, Ragni, Margaret, Kulkarni, Roshni, Ozelo, Margareth C., Mahlangu, Johnny, Shapiro, Amy, P’Ng, Stephanie, Chambost, Hervé, Nolan, Beatrice, Bennett, Carolyn, Matsushita, Tadashi, Winding, Bent, Fruebis, Joachim, Yuan, Huixing, Rudin, Dan, Oldenburg, Johannes
• Format: Journal Article
• Language: English
• Published: England Wiley Subscription Services, Inc 01.11.2020; Wiley
• Subjects: bleed rate; Coagulation factors; extended half‐life; factor IX; Factor IX deficiency; Fc receptors; Fusion protein; haemophilia B; Hematology; Hemophilia; Human health and pathology; individualized prophylaxis; Life Sciences; Pediatrics; perioperative haemostasis; Prophylaxis; rFIXFc; Safety; factor IX; haemophilia B; bleed rate; rFIXFc; extended half-life; perioperative haemostasis; individualized prophylaxis

Introduction Recombinant factor IX Fc fusion protein (rFIXFc) has demonstrated efficacy for treatment of haemophilia B in the Phase 3 B‐LONG and Kids B‐LONG studies. However, long‐term rFIXFc safety and efficacy data have not yet been reported. Aim To report long‐term rFIXFc safety and efficacy in s...